乳腺磁共振成像在接受新辅助化疗的大导管癌患者中与较少乳房切除术相关,但在小叶癌中并非如此
该研究基于荷兰癌症登记处2011-2013年接受新辅助化疗的I-III期浸润性乳腺癌患者,评估乳腺磁共振成像(MRI)使用对手术结局的影响。3433例中2879例(83.9%)使用乳腺MRI。在导管癌中,按cT分期分层后,MRI使用与cT3肿瘤最终乳房切除术的显著较低OR相关(OR 0.45,95%CI 0.21-0.99);切缘受累和对侧乳腺癌检出与MRI使用无关。结论认为MRI使用与降低的乳房切除术率相关,尤其在大浸润性导管肿瘤患者中,但在小叶癌患者中并非如此。
要点
- 3433例接受新辅助化疗的乳腺癌患者中,2879例(83.9%)使用了乳腺MRI。
- 导管癌cT3患者中,MRI使用与最终乳房切除术的OR 0.45(95%CI 0.21-0.99)相关。
- 小叶癌患者中未观察到MRI使用与乳房切除术率降低的关联。
核心结论
- 在接受新辅助化疗的患者中,乳腺MRI使用与降低的乳房切除术率相关,尤其在大浸润性导管肿瘤患者中,但在小叶癌患者中并非如此。
研究设计与样本
- 研究基于荷兰癌症登记处,纳入2011-2013年荷兰18-70岁接受新辅助化疗的I-III期浸润性乳腺癌患者,排除cT4肿瘤。
- 共分析3433例患者,采用多变量分析评估乳腺MRI使用对手术治疗、切缘和对侧乳腺癌检出的影响。
主要发现
- 3433例患者中2879例(83.9%)接受了乳腺MRI。
- 与50-70岁相比,18-50岁与乳腺MRI使用增加相关(OR 1.42;95%CI 1.17-1.71)。
- 与cT1-2肿瘤相比,cT3肿瘤与乳腺MRI使用增加相关(OR 1.46;95%CI 1.15-1.86)。
- 与单灶性相比,多灶性与乳腺MRI使用增加相关(OR 1.30;95%CI 1.04-1.61)。
- 在导管癌中,按cT状态分层后,cT3肿瘤中乳腺MRI使用与最终乳房切除术的显著较低OR相关(OR 0.45,95%CI 0.21-0.99)。
关键数值与推荐
- 乳腺MRI使用与cT3导管癌最终乳房切除术的OR 0.45(95%CI 0.21-0.99)相关。
- 乳腺MRI使用与切缘受累无关。
- 乳腺MRI使用与对侧乳腺癌检出无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the impact of breast magnetic resonance imaging (MRI) use on surgical outcome per histological breast cancer subtype in patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: All patients aged 18-70 years who underwent neoadjuvant chemotherapy for stage I-III invasive breast cancer in the Netherlands in the years 2011-2013 were identified from the Netherlands Cancer Registry. Patients with cT4 tumours were excluded from the analysis. Use of breast MRI and impact on surgical treatment, resection margins and detection of contralateral breast cancer were analysed by multivariable analyses. RESULTS: Breast MRI was performed in 2879 (83.9%) out of 3433 patients treated with neoadjuvant chemotherapy. Younger age (odds ratio [OR] 1.42; 95% confidence interval [CI] 1.17-1.71 for 18-50 years compared with 50-70 years), larger tumour stage (OR 1.46 [95% CI 1.15-1.86] for cT3, compared to cT1-2 tumours) and multifocality (OR 1.30; 95% CI 1.04-1.61, versus unifocality) were associated with increased breast MRI use. In ductal breast cancer, after stratification for cT-status, breast MRI use is associated with a significant lower OR for mastectomy as final surgery in cT3 tumours (OR 0.45, 95% CI 0.21-0.99). Resection margin involvement and detection of contralateral breast cancer were not associated with breast MRI use. CONCLUSION: In patients treated with neoadjuvant chemotherapy, the use of breast MRI was associated with a reduced mastectomy rate, particularly in patients with large invasive ductal breast tumours but not in patients with lobular breast cancer.
引用
- Vriens IJH, Keymeulen K, Lobbes MBI, et al. Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers. Eur J Cancer. 2017. PMID: 28618304. doi:10.1016/j.ejca.2017.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。